Anupam Rasayan India Ltd
NSE: ANURAS BSE: 543275
₹1145.40
+5.80 (0.51%)
Sat, 07 Nov 2026, 08:41 pm
Market Cap (in Cr)12978.88
PE Ratio74.48
Dividend0.13
Health Technology
Pharmaceuticals: Major
24.5KAnupam Rasayan India Income Statement
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 3.41B | 5.01B | 5.29B | 8.11B | 10.66B | 15.90B | 14.68B | 14.33B |
| Gross profit | 817.20M | 988.10M | 1.38B | 1.85B | 2.99B | 4.51B | 4.02B | 4.05B |
| Operating expenses (excl. COGS) | -250.15M | -277.20M | -315.39M | -396.20M | -584.21M | -936.36M | -1.01B | -1.04B |
| Selling/general/admin expenses, total | -247.58M | -277.18M | -311.75M | -387.64M | -583.59M | -934.61M | -1.01B | -1.04B |
| Research & development | — | — | — | — | — | -273.26M | -107.00M | -32.00M |
| Selling/general/admin expenses, other | -247.58M | -277.18M | -311.75M | -387.64M | -583.59M | -661.35M | -899.75M | -1.01B |
| Other operating expenses, total | -2.57M | -20.00K | -3.64M | -8.56M | -620.00K | -1.75M | -5.78M | -1.06M |
| Operating income | 567.05M | 710.90M | 1.07B | 1.45B | 2.41B | 3.57B | 3.01B | 3.01B |
| Non-operating income, total | -69.39M | -53.73M | -352.86M | -452.52M | -196.55M | -511.58M | -590.50M | -1.03B |
| Interest expense, net of interest capitalized | -133.67M | -171.65M | -399.36M | -650.18M | -292.16M | -540.16M | -857.55M | -1.10B |
| Interest capitalized | 194.16M | 275.89M | 124.35M | 48.66M | 0 | 155.37M | 187.73M | 207.18M |
| Non-operating income, excl. interest expenses | 64.28M | 117.92M | 44.63M | 189.57M | 95.61M | -22.19M | 248.91M | 54.85M |
| Non-operating interest income | 10.37M | 49.43M | 42.27M | 18.07M | 37.15M | 265.45M | 121.50M | 115.57M |
| Miscellaneous non-operating expense | 53.91M | 68.49M | 2.36M | 171.50M | 58.46M | -287.64M | 127.41M | -60.72M |
| Unusual income/expense | 0 | 0 | 1.87M | 8.09M | 0 | 50.77M | 18.14M | 8.65M |
| Pretax income | 497.66M | 657.17M | 716.67M | 1.00B | 2.21B | 3.06B | 2.42B | 1.98B |
| Taxes | -94.25M | -155.08M | -184.61M | -297.08M | -696.77M | -908.16M | -743.35M | -378.79M |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 | -360.01M | -388.30M | -666.23M |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 413.07M | 492.48M | 532.06M | 702.96M | 1.52B | 1.81B | 1.29B | 933.49M |
| Net income | 413.07M | 492.48M | 532.06M | 702.96M | 1.52B | 1.81B | 1.29B | 933.49M |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 413.07M | 492.48M | 532.06M | 702.96M | 1.52B | 1.81B | 1.29B | 933.49M |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - |
| EBITDA | 742.79M | 936.18M | 1.36B | 1.97B | 3.01B | 4.28B | 3.81B | 4.03B |
| EBIT | 567.05M | 710.90M | 1.07B | 1.45B | 2.41B | 3.57B | 3.01B | 3.01B |
| Total operating expenses | -2.85B | -4.30B | -4.22B | -6.66B | -8.25B | -12.33B | -11.68B | -11.31B |
| Prepaid expenses | 18.72M | 17.73M | 11.13M | 61.24M | 107.60M | 148.99M | 188.75M | 269.97M |
| Deferred income, current | 270.00K | 270.00K | 90.00K | 90.00K | — | 12.26M | 7.29M | 16.30M |
| Capital and operating lease obligations | 0 | 0 | 322.32M | 322.32M | 268.94M | 268.94M | 398.76M | 954.61M |
| Operating lease liabilities | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 101.75M | 136.89M | 190.83M | 243.82M | 546.49M | 760.29M | 1.16B | 1.10B |
| Deferred income, non-current | — | — | — | — | — | — | — | — |
| Minority interest | 0 | 0 | 0 | 0 | 0 | 1.35B | 1.70B | 2.31B |
| Change in accrued expenses | — | — | — | — | — | — | — | — |
| Common dividends paid | 0 | 0 | 0 | 0 | -99.92M | -245.55M | -263.11M | -134.19M |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
